ADX 71149

Drug Profile

ADX 71149

Alternative Names: ADX-71149; JNJ-40411813; JNJ-mGluR2-PAM

Latest Information Update: 04 Nov 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Addex Pharmaceuticals
  • Developer Addex Therapeutics; Janssen Pharmaceuticals
  • Class Antidepressants; Antipsychotics; Anxiolytics; Piperidines; Pyridines; Small molecules
  • Mechanism of Action Metabotropic glutamate receptor 2 modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Epilepsy
  • Preclinical Panic disorder
  • Discontinued Major depressive disorder; Psychiatric disorders; Schizophrenia

Most Recent Events

  • 04 Sep 2018 Preclinical trials in Panic disorder in Switzerland (PO) before September 2018
  • 24 Jun 2018 Biomarkers information updated
  • 27 Feb 2017 Addex Therapeutics and Janssen Pharmaceuticals plan a phase IIa proof of concept trial for Epilepsy
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top